Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (T2DM)~* Treated with either stable dose of metformin alone \> or = to 1500mg/day or stable dose of insulin \> or = to 30 units/day and up to 2 OAD medications for at least 8 weeks~* Hemoglobin A1c (HbA1c) 7.5% to 10.5% at screening~* Body mass index (BMI) \< or = to 45 kg/m2~Exclusion Criteria:~* For patients who enter the study taking a stable dose of metformin, history of taking OAD medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening~* For patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 OAD medications for 8 weeks prior to screening.~* Use of sulfonylureas during the 8 weeks prior to screening~* Prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (SGLT-2) inhibitor~* Ingestion of any medication know to affect glucose metabolism for \>7 consecutive days during the 3 months prior to screening~* Ingestion of prescription or over the counter weight loss medication during 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Farxiga with metformin or insulin (Type: EXPERIMENTAL): Farxiga with metformin (\>/=1500mg/day) or insulin (\>/=30 units/day) and up to 2 OAD medications
- Placebo with metformin or insulin (Type: PLACEBO_COMPARATOR): Placebo with metformin (\>/=1500mg/day) or insulin (\>/=30 units/day) and up to 2 OAD medications

Based on this trial design, predict the completion outcome and termination type (if applicable).